Xenetic Biosciences(XBIO) - 2024 Q2 - Quarterly Results

Financial Performance - Xenetic Biosciences, Inc. reported financial results for the three months ended June 30, 2024[3]. - The company issued a press release on August 14, 2024, detailing its financial performance and business updates[3]. - The company has not provided specific numerical financial results in the extracted documents[2]. Forward-Looking Statements - Forward-looking statements indicate expectations for future performance, subject to various risks and uncertainties[4]. - The press release and forward-looking statements are intended to provide insights into the company's future strategies and expectations[4]. Risks and Uncertainties - The company is subject to market factors and economic conditions that may impact its operations and product development[4]. - Risks include public health issues, geopolitical events, and regulatory challenges that could affect performance[4]. Compliance and Reporting - The report was signed by James Parslow, Interim Chief Executive Officer & Chief Financial Officer[6]. - The company is registered with the SEC and complies with reporting requirements[1]. - The press release is incorporated by reference in the Form 8-K filing, but the information is not deemed "filed" under the Securities Exchange Act[3].